Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marfan's syndrome.

Daniel P Judge1, Harry C Dietz

  • 1Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.

Lancet (London, England)
|December 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Who declines genetic counseling? An assessment of genetic counseling declination among individuals participating in a population-wide genomic screening program.

Patient education and counseling·2026
Same author

Acoramidis for the management of transthyretin amyloid cardiomyopathy: Clinical evidence and implications for pharmacist-led care.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

JACC. CardioOncology·2026
Same author

Spontaneous spinal CSF leaks: a rare variant exome sequencing study and functional analysis.

The Lancet. Neurology·2026
Same author

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal of cardiac failure·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Marfan syndrome, a connective tissue disorder, stems from fibrillin-1 mutations. Research reveals altered transforming growth factor beta (TGFbeta) regulation contributes to disease, suggesting TGFbeta antagonists as potential therapies.

Area of Science:

  • Genetics and Molecular Biology
  • Connective Tissue Disorders
  • Cardiovascular Genetics

Background:

  • Marfan syndrome is a genetic disorder affecting connective tissue, primarily caused by mutations in the fibrillin-1 gene.
  • Key clinical features include aortic aneurysms, lens dislocation, and skeletal overgrowth.
  • Despite advances, significant morbidity and mortality persist in affected individuals.

Purpose of the Study:

  • To elucidate the pathogenetic mechanisms underlying Marfan syndrome using genetically defined mouse models.
  • To identify key molecular pathways involved in fibrillin-1 deficiency.
  • To explore potential therapeutic targets for Marfan syndrome.

Main Methods:

  • Utilized genetically modified mouse models with fibrillin-1 deficiency.

Related Experiment Videos

  • Investigated the role of extracellular matrix protein alterations.
  • Analyzed the involvement of cytokine signaling pathways, specifically transforming growth factor beta (TGFbeta).

    • Main Results:

    • Fibrillin-1 deficiency initiates a pathogenic cascade.
    • Altered regulation of transforming growth factor beta (TGFbeta) is a critical factor in disease manifestation.
    • Mouse models provide insights into disease mechanisms.

    Conclusions:

    • Understanding fibrillin-1 deficiency's role in Marfan syndrome is advancing.
    • TGFbeta dysregulation is a key pathway, indicating potential therapeutic strategies using TGFbeta antagonists.
    • Findings may extend to non-syndromic conditions with overlapping phenotypes.